An Overview of the Stratified Economics of Stratified Medicine

Mark R. Trusheim, Ernst R. Berndt

NBER Working Paper No. 21233
Issued in June 2015
NBER Program(s):Health Care

The economics of stratified medicine depend critically on setting the cut-off score of the companion diagnostic (CDx). This action integrates scientific, clinical, ethical and commercial considerations, and simultaneously determines the value of the stratified medicine to developers, providers, payers and patient. Setting a high cut-off ensures a larger response by excluding more non-responders but also denies treatment to patients who would respond. This creates ethical and clinical concerns, and limits market size. Setting a low cut-off includes more patients who can benefit but includes more non-responders with commensurate costs, side effects and lost time. CDx’s capture little value under current reimbursement and exclusivity protections. Combined with low CDx investment incentives for generic drug manufacturers, little CDx development occurs for older legacy drugs. Therefore payers face an asymmetric situation of novel stratified medicines raising public health and payers’ costs, but no CDx’s for legacy treatments to reduce costs. It would be in payers’ interests to rediscover their heritage of direct investment in diagnostic development.

download in pdf format
   (639 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w21233

Users who downloaded this paper also downloaded* these:
Lichtenberg w21239 The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011
Egan and Philipson w20330 Health Care Adherence and Personalized Medicine
Conti and Berndt Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007
Trusheim, Aitken, and Berndt w16014 Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
Faust, Gilchrist, Wright, and Zakrajšek w16725 Credit Spreads as Predictors of Real-Time Economic Activity: A Bayesian Model-Averaging Approach
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us